Medical Devices Provider Boston Scientific Cardiovascular Segment Sees Traction In Q3, Company Adjusts Annual Outlook

Boston Scientific Corp BSX generated Q3 revenues of $3.53 billion, beating the Wall Street estimate of $3.48 billion.

The sales increased 11.2% on a reported basis, 11.1% on an operational basis, and 10.2% on an organic basis, beating the management of approximately 8.5% - 10.5% (7% - 9% organic).

The company earned an adjusted EPS of $0.50, beating the consensus of $0.48 and management estimate of $0.46 - $0.48.

Revenues from MedSurg increased 10.6% to $1.34 billion (9.4% organic), and the Cardiovascular segment generated $2.19 billion, +11.6% (10.6% organic).

The adjusted gross margin was 70.17%, down from 70.66%, and the adjusted operating margin expanded from 25.55% to 26.06%.

Outlook: Boston Scientific revises FY23 revenue growth guidance to 11% (on the reported basis and organic basis) versus prior guidance of 10.5%-11.5% and 10%-11%, respectively.

The company forecasts adjusted EPS of $1.99 - $2.02 versus the consensus of $2.00 and the prior guidance of $1.96 - $2.00.

For Q4, the company expects revenue growth of 9%-11% (reported) and 8%-10% (organic), with adjusted EPS of $0.49-$0.52 and consensus of $0.52.

Price Action: BSX shares are up 0.35% at $50.17 on the last check Thursday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!